Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Buy” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned an average rating of “Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and two have assigned a strong buy recommendation to the company.

Several research analysts have commented on the company. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, Zacks Research cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY opened at $10.56 on Friday. The stock has a market cap of $41.50 billion, a PE ratio of -117.32, a price-to-earnings-growth ratio of 5.27 and a beta of 0.69. Bayer Aktiengesellschaft has a fifty-two week low of $4.80 and a fifty-two week high of $10.71. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The stock has a fifty day moving average of $8.92 and a 200-day moving average of $8.32.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.